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Abstract: Opioid rotation is a common and necessary clinical practice in the management of 
chronic non-cancer pain to improve therapeutic efficacy with the lowest opioid dose. When dose 
escalations fail to achieve adequate analgesia or are associated with intolerable side effects, 
a trial of a new opioid should be considered. Much of the scientific rationale of opioid rotation 
is based on the wide interindividual variability in sensitivity to opioid analgesics and the novel 
patient response observed when introducing an opioid-tolerant patient to a new opioid. This 
article discusses patient indicators for opioid rotation, the conversion process between opioid 
medications, and additional practical considerations for increasing the effectiveness of opioid 
therapy during a trial of a new opioid. A Patient vignette that demonstrates a step-wise approach 
to opioid rotation is also presented.
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Introduction
Patients treated with opioid analgesics exhibit broad differences in sensitivity to the 
analgesic and nonanalgesic effects of these medications.1 Such differences necessitate 
a highly individualized approach to therapy, with the goal of balancing the therapeutic 
effects with the side effects. When dose escalations are associated with inadequate 
analgesia or intolerable side effects, a planned switch from one opioid to another 
opioid can be considered.2–4 This treatment approach, known as “opioid rotation,” is 
a   common clinical practice intended to improve a patient’s response to treatment.3 
Rotating to a new opioid may be necessary at any time after the initiation of therapy. 
Clinical guidelines recommend opioid rotation for patients with chronic pain who 
experience a decline in therapeutic efficacy with their current opioid, or for patients 
who experience inadequate efficacy or intolerable adverse events (AEs) during dose 
titration.2
The rationale for opioid rotation is based on the wide interindividual variability 
in sensitivity to opioid analgesics and the novel patient response observed when 
introducing an opioid-tolerant patient to a new opioid.1,2,4,5 Specifically, patients may 
respond very differently with respect to analgesic and nonanalgesic effects (eg, adverse 
effects).5 This variability is the outcome of a complex interaction between drug-related 
and biological factors.4,5 The differential activities of opioid analgesics are determined, 
at least in part, by the relative binding affinities to the different opioid receptor classes 
and subtypes. Opioids used for moderate-to-severe chronic non-cancer pain exert 
their analgesic effects primarily via mu-opioid receptors, and some data exist for the International Journal of General Medicine 2012:5 submit your manuscript | www.dovepress.com
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existence of different subtypes of mu-opioid receptors.6,7 
Accordingly, a patient who has displayed marked tolerance to 
one opioid may display incomplete cross-tolerance to another 
opioid with a different receptor-binding profile.8,9 This can be 
manifested clinically as a restoration of analgesic sensitivity 
upon administration of a different opioid. Individual variation 
in receptor distribution and sensitivity likely influences the 
wide range of doses required to obtain adequate analgesia 
with a given opioid. Theoretically, matching the patient with 
the proper mu-opioid receptor agonist will allow patients to 
obtain adequate analgesia with tolerable AEs at the lowest 
possible dose.
Commonly used opioids for managing moderate-  to-  severe 
chronic non-cancer pain include immediate-release (IR) and 
extended-release (ER) formulations of hydromorphone, 
morphine sulfate, oxycodone,   oxymorphone, and tapentadol, 
as well as transdermal fentanyl.10–19 Treatment strategies 
to manage this type of pain include combinations of an 
ER and IR opioid to provide baseline and supplemental 
analgesia for breakthrough pain.2 The selection of the opi-
oid should take into account such factors as the patient’s 
medical status, age, previous exposure to opioid therapy, 
and access to medication, as well as cost and convenience 
of administration.2,4 The patient’s likelihood for misuse, 
abuse, and overdose should also factor in the treatment deci-
sion.20 Regardless of which opioid is selected, patients will 
likely require rotation to a new opioid at some point during 
  treatment to maintain analgesic efficacy. The following 
discussion provides an approach to implement opioid 
rotation in patients with chronic non-cancer pain, as well 
as clinical considerations in the practical management of 
patients undergoing opioid rotation. In addition, a Patient 
vignette is presented to illustrate key decision points in 
opioid rotation.
Approach to opioid rotation
Deciding when to initiate opioid rotation
Attempts at dose escalation often precede opioid rotation, as this 
is a logical next step for pain patients   experiencing inadequate 
analgesia with their current opioid dose.2,3   However, the clini-
cal utility of administering higher opioid doses is limited by 
several factors, including an increase of treatment-related 
AEs (ie, nausea, constipation, somnolence).2,10–17 In addition, 
no current standard definition for a “high dose” exists, and 
there is a lack of substantial evidence-based guidance for safe 
prescribing practices at higher doses.2 Furthermore, although 
there is no theoretical ceiling dose for pure opioid analgesics,2 
with repeated dose escalation and higher daily opioid doses, 
there is an increased risk for overdose death.21,22 In a study 
of chronic pain patients, those who received a total daily 
dose of $50 mg/day and $100 mg/day morphine equivalent 
had an approximately 5- and 7-times greater risk of opioid 
overdose death compared with patients receiving ,20 mg/day 
  morphine equivalent, respectively.21
Patient vignette Opioid rotationa
Patient 42-year-old patient  
Primary diagnosis: neuropathic pain from multiple back surgeries for lumbosacral spine disease
Initial opioid treatment Baseline opioid: 40 mg/8 hours oxycodone er
Supplemental analgesic: 5/500 mg hydrocodone Ir/APAP, up to 6/day as needed 
rationale for rotation to a  
new opioid
Inadequate pain control with current medications 
Clinician concern over risks associated with total daily dose of APAP
Selected opioid for rotation Baseline opioid: hydromorphone er 
Supplemental analgesic: oxycodone Ir
Conversion to hydromorphone er Previous total daily dose (baseline opioid): 
 
er oxycodone morphine equivalent dose:
Ir hydrocodone morphine equivalent dose:
Total daily morphine equivalent dose:
Conversion ratio to hydromorphone erb: 
New total daily dose:
Starting dose (with ~50% additional reduction  
of equianalgesic dose):
Stable opioid dose:
120 mg/day oxycodone er 
30 mg/day hydrocodone Ir 
240 mg/day 
60 mg/day 
300 mg/day 
5:1 morphine equivalent:hydromorphone 
60 mg/day hydromorphone ER 
32 mg/day (2 × 16 mg tablets) hydromorphone erc 
 
48 mg/day hydromorphone ER titrated over next 
2 weeksd
Outcome Well tolerated with adequate around-the-clock pain control
Notes: aThis example is taken from the author’s experience with one patient during a clinical trial; bclinical trials of patients with chronic pain support the efficacy and safety 
of 5:1 morphine equivalent:hydromorphone er conversion ratio23,24; can alternative conversion strategy would be to administer 36 mg/day (3 × 12 mg tablets) hydromorphone 
er and titrate to 48 mg/day over the next 2 weeks; dprovided 5 mg/day oxycodone Ir, up to 3/day as needed for supplemental analgesia.
Abbreviations: er, extended-release; Ir, immediate-release; APAP, acetaminophen.International Journal of General Medicine 2012:5 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
13
Opioid rotation
For patients maintained on combination opioid prod-
ucts containing acetaminophen (APAP), careful con-
sideration should also be given to unencumbered dose 
increases. In response to reports of severe liver injury 
associated with high doses of APAP, the US Food and Drug 
Administration (FDA) recently limited the amount of APAP 
in oral combination products to 325 mg/dose, and the total 
daily dose to 4000 mg/day.25 Additional recommenda-
tions call to further limit the total daily dose of APAP to 
2600 mg/day.26
Intolerable AEs or lack of effective analgesia fol-
lowing dose escalation may necessitate rotation to a 
new opioid (Table 1).2,3 It is important to note that this 
practice is not limited to the introduction of one new 
opioid, but may be approached as one trial in a sequence 
of rotations.27 A lack of analgesia or an increase in AEs 
with the new opioid might indicate the need for a second, 
or additional, rotation.4 In a retrospective chart review of 
chronic pain patients prescribed long-acting or ER opioids, 
the   cumulative   percentage of patients who achieved an 
effective, well-tolerated opioid dose increased from 36% 
after the first rotation to 80% after the fourth rotation 
(Figure 1).27
Initiating opioid rotation and patient 
assessment
The choice of the new opioid should be individualized and 
based on the patient’s medical status and history, previous 
exposure to opioids, access to medication, potential risk for 
abuse, and other psychosocial factors.3 The starting dose 
of the new opioid is an equally important consideration. 
  Analgesic potency varies among opioids; therefore, 
  equianalgesic   dosing tables may be used to calculate the 
new starting dose (Table 2).23,24,28,29 Although these tables are 
a reasonable starting point for determining an equianalgesic 
dose of a new opioid, certain limitations should be acknowl-
edged.28 The relative potencies were derived primarily from 
studies of patients with acute pain, and often with   intravenous 
opioid administration.28 They also do not account for 
  individual patient variability.28 It also has been recognized 
that equianalgesic doses can underestimate the actual potency 
of the molecule.3 An additional dose reduction of 25% to 
50% below the equianalgesic dose has therefore been recom-
mended (see Patient vignette) to account for underestimated 
potency and incomplete cross-tolerance among opioids.3 
Although a more conservative approach may help safeguard 
against adverse outcomes in patients particularly sensitive to 
the new   opioid, a 50% additional reduction may not provide 
adequate analgesia for some patients. For patients undergoing 
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Figure 1 Cumulative percentage of patients achieving an effective opioid dose with 
opioid rotation.27
Adapted  with  permission  from  Quang-Cantagrel  et  al.  Opioid  substitution  to 
improve the effectiveness of chronic noncancer pain control: a chart review. Anesth 
Analg. 2000;90(4):933–937.
Table 2 Original equianalgesic dose table28
Medication Equianalgesic (mg) doses, route  
of administration
Intramuscular/intravenous/
subcutaneous
Oral
Morphinea 10 mg 60 mg
hydromorphoneb 1.5 mg 7.5 mg
Oxycodone 20–30 mg
Oxymorphonec 1 mg 15 mg
Levorphanol 2 mg 4 mg
Methadoned 10 mg 20 mg
Fentanyl 50–100 μge
Notes:  aPotency  estimates  relative  to  the  original  dose  table  have  undergone 
little change; however, the oral morphine dose is often revised to 20 to 30 mg, 
as the original acute dosing data do not apply to chronic opioid therapy; balthough 
the  morphine:hydromorphone  equianalgesic  potency  ratio  is  as  high  as  8:1  for 
hydromorphone  Ir,  the  equianalgesic  potency  ratio  for  hydromorphone  er  is 
5:123,24,29;  coxymorphone  equianalgesic  dose  for  rectal  administration:  10  mg; 
din clinical practice, methadone appears to be more potent than originally estimated, 
warranting caution during rotation (see text: Rotation to Methadone); edose ratio only 
applicable to intravenous and subcutaneous administration.
reprinted from J Pain Symptom Manage, vol 38, issue 3, Knotkova et al, Opioid 
rotation: the science and the limitations of the equianalgesic dose table, p426–439, 
Copyright (2009), with permission from elsevier.
Table 1 Major reasons for opioid rotation3
Major reasons for opioid rotation
Development of intolerable Aes  
with current opioid
Patient displays drug-aberrant 
behavior(s)
Lack of analgesia following dose 
escalation
Patient prefers alternative route   
of administration
Occurrence of drug–drug  
interactions
Financial limitations or access 
barriers to certain medications
reprinted from J Pain Symptom Manage, vol 38, issue 3, Fine et al, Ad hoc expert 
Panel on evidence review and Guidelines for Opioid rotation. establishing “best 
practices” for opioid rotation: conclusions of an expert panel, p418–425, Copyright 
(2009), with permission from elsevier. 
Abbreviation: Aes, adverse events.International Journal of General Medicine 2012:5 submit your manuscript | www.dovepress.com
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rotation to a new opioid, inadequate analgesia can potentially 
manifest as breakthrough pain or symptoms of withdrawal 
(concepts discussed in detail below).3 An IR opioid may 
therefore be given as a supplemental analgesic.3
From this author’s clinical experience, converting 
patients to 66% of the previous total daily opioid dose, or 
a dose reduction of 33% below the equianalgesic dose, is 
suggested. In addition, patients can be given an IR opioid 
for supplemental analgesia, dosed at 33% of the new total 
daily opioid dose. In line with the principles of responsible 
opioid prescribing, the individual clinical decision-making 
process should be based on a comprehensive patient assess-
ment, including past opioid experience and the agreed upon 
treatment plan.30
Following the initial calculation of the equianalgesic 
dose, a number of other assessments should be made before 
administering the new opioid dose. The patient’s current 
pain intensity, side effect profile, and medical status should 
be assessed, in addition to other medical and psychosocial 
factors that may affect the outcome of treatment. In certain 
cases, an additional 15% to 30% increase or decrease of the 
daily opioid dose may be applied (Table 3).3
Clinical considerations
Opioid selection
As patients managed with chronic opioid therapy likely 
receive concomitant medications, there is a significant risk of 
drug–drug interactions.4,31 Opioids that undergo cytochrome 
P450 (CYP450) isoenzyme metabolism have a greater risk 
of interaction with concomitant medications metabolized 
by the same CYP450 pathway.4 Of the ER or controlled-
release opioids, hydromorphone, morphine, oxycodone, 
and tapentadol appear to have little to no interaction with 
the CYP450 pathway,10,12,13,15,19,32 indicating a lower risk of 
drug–drug interactions with certain medications.
While it is not possible to predict who is likely to 
respond to a particular opioid, the patient’s history of opioid 
exposure may provide important insights. For example, 
in a patient undergoing a rotation from IR oxycodone to 
controlled-release oxycodone, there is the potential for a more 
favorable therapeutic response based on the patient’s previ-
ously demonstrated tolerability of this molecule. A similar 
“molecule matching” approach may also be applicable when 
rotating a patient from hydrocodone to hydromorphone. 
Hydrocodone is metabolized, in part, to hydromorphone 
through the CYP450 (2D6) pathway.33 Patients previously 
maintained on hydrocodone, and particularly hydrocodone-
treated patients who are CYP2D6 rapid metabolizers, 
theoretically may experience favorable tolerability when 
converted to hydromorphone.32,34 Likewise, patients previ-
ously maintained on oxycodone, which is metabolized, in 
part, to oxymorphone,35 may be more likely to respond to 
a rotation to oxymorphone. The validity of this “molecule 
matching” approach, however, requires confirmation from 
systematic studies.
Supplemental analgesia to manage 
breakthrough pain
Although breakthrough pain in patients with chronic non-
cancer pain has not been fully characterized, recent studies 
show a prevalence of 48% to 74% in this patient population, 
despite having well-controlled baseline persistent pain.36–38 
Patients report an average of 1 to 2 episodes per day, with a 
median time to maximum intensity of 1 to 10 minutes and a 
median episode duration of 45 minutes to 1 hour.37,38
Patients undergoing opioid rotation may experience break-
through pain, and this type of pain should undergo a separate 
assessment from the patient’s baseline   persistent pain.2,3 
Table 3 expert consensus for a two-step approach to opioid 
rotation3
Step 1 •    Calculate the equianalgesic starting dose of the new 
opioid using an equianalgesic dosing table
•    Apply an additional dose reduction of 25% to 50%  
to the equianalgesic starting dosea
○    reduction closer to 50% if the patient was previously 
receiving a relatively high opioid dose, is not 
Caucasian, or is elderly, or medically frail
○    reduction closer to 25% in patients without the 
aforementioned characteristics or in patients 
changing only the route of administration
Step 2 •    Assess the patient’s current pain severity, occurrence 
of adverse events, medical status, and other medical or 
psychosocial factors influencing therapeutic efficacy
○    Initiate opioid therapy with the starting dose 
determined using step 1 or apply an additional 
15% to 30% dose increase or decrease based on 
the likelihood of achieving adequate analgesia with 
tolerable adverse events and without inducing 
withdrawal
•    Consider providing supplemental opioid analgesia 
during the titration process of 5% to 15% of the total 
daily opioid doseb
•    Frequently monitor for patient response and individual 
dose titration
Notes: aGreat caution is needed when initiating treatment with methadone.2 A 75% 
to 90% additional dose reduction or inpatient monitoring is recommended with 
an equianalgesic starting dose of $100 mg/day of methadone3; bno additional dose 
reduction is recommended when rotating to transdermal fentanyl when using the 
conversion tables provided in the drug’s prescribing information.
reprinted from J Pain Symptom Manage, vol 38, issue 3, Fine et al, Ad hoc expert 
Panel on evidence review and Guidelines for Opioid rotation. establishing “best 
practices” for opioid rotation: conclusions of an expert panel, p418–425, Copyright 
(2009), with permission from elsevier.International Journal of General Medicine 2012:5 submit your manuscript | www.dovepress.com
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As previously mentioned, an IR opioid may be provided for 
supplemental analgesia when initiating a new opioid trial (see 
Patient vignette).3 However, the total daily dose including 
the primary opioid and the supplemental IR opioid should 
be considered, given the increased risk of AEs and overdose 
with high daily doses.21
rotation to methadone
Additional caution must be taken if rotating a patient’s 
therapy to methadone.2,3 Methadone is indicated for the 
treatment of moderate-to-severe pain that is uncontrolled 
with non-opioid analgesics.2 The 4- to 8-hour duration of 
analgesic effect makes methadone amenable for use in 
chronic pain management.39 However, the elimination half-
life of the molecule varies widely across patients and may 
last up to 59 hours.39
In clinical studies, methadone appears to be substantially 
more potent than previously believed, particularly when rotat-
ing from another mu-opioid.40 Specifically, methadone has 
been reported to reverse mu-agonist opioid tolerance, and 
deaths have been reported following conversion to methadone 
in patients receiving other chronic opioid therapy.28,41 The 
risk of serious, life-threatening AEs, such as respiratory 
depression and cardiac arrhythmias, can persist beyond the 
duration of analgesic effects.39 From 1999–2006, there was 
an approximate 7-fold rise in methadone-related deaths in the 
US.42 An in-depth knowledge of the variable pharmacokinet-
ics and associated risks of methadone is therefore essential, 
and current guidelines underline the importance of cautious 
initiation and dose titration.2
Managing withdrawal
Symptoms of withdrawal can manifest following a dose 
reduction in chronic pain patients who are tolerant to, and 
physically dependent on, opioids.43 Patients who undergo 
rotation may experience withdrawal due to the additional 
reduction in the equianalgesic dose, necessitating the   ability 
to recognize and manage associated signs and   symptoms.3 
This can include such autonomic signs as diarrhea, 
rhinorrhea, and piloerection, as well as central neurologic 
arousal characterized by sleeplessness, irritability, and 
  psychomotor agitation.43 As the dose is individually titrated 
to adequate analgesia, however, the symptoms of withdrawal 
can potentially dissipate.
Policies regulating prescription opioid use
Patients with chronic non-cancer pain require compre-
hensive treatment, given the common accompaniment of 
complex comorbidities.2 All health care providers managing 
patients with opioid analgesics should adhere to good pre-
scribing principles to ensure that the benefits outweigh the 
risks.2 This includes, but is not limited to, the ability and 
resources to assess and manage opioid-related AEs and other 
risks such as misuse, abuse, and diversion.2 Furthermore, 
compliance with federal and individual state policies govern-
ing prescription opioid use is fundamental.44
To ensure that the therapeutic benefit outweighs the risks, 
the FDA recently announced a classwide Risk Evaluation 
and Mitigation Strategy (REMS) for all long-acting and ER 
opioids.45 Under this program, prescribers will be required 
to undergo training on appropriate and safe prescribing 
practices.45 Since opioid rotation requires the knowledge to 
safely prescribe a range of opioid formulations, education 
provided through this REMS should act as a complementary 
measure. Patients will also receive materials and undergo 
counseling on safe use.45 Importantly, this information will 
include points on proper opioid disposal.45 As rotation from 
one opioid to another may leave unused doses, patients should 
be advised to flush their unused medication to avoid the risk 
of accidental exposure.46
Although not currently implemented, future legislation 
may require a prescriber to undergo training as part of US 
Drug Enforcement Administration registration.47 Preemptive 
and active participation in classwide REMS for ER opioids 
is therefore encouraged.
Conclusion
Current scientific knowledge limits the ability to predict 
which patient will respond optimally to which opioid 
analgesic. Opioid rotation is therefore a necessary practice 
in the management of chronic non-cancer pain to achieve 
therapeutic efficacy with the lowest possible dose. Even 
patients who respond favorably to initial opioid therapy may 
require rotation to a new opioid over time to maintain adequate 
analgesia. Importantly, this practice also minimizes the risks 
of AEs and overdose associated with frequent dose escalations 
and higher daily opioid doses. Clinical judgment based on the 
individual patient should be used when determining the new 
opioid for rotation, and careful attention should be taken to 
individualize the starting dose. Guided by state policies and 
responsible prescribing practices, opioid rotation can be safely 
and effectively implemented in clinical practice.
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